Author + information
- Pooja Dewan, MBChBa,
- Rasmus Rørth, MDa,b,
- Pardeep S. Jhund, MBChB, PhDa,
- Joao Pedro Ferreira, PhDc,
- Faiez Zannad, PhDc,
- Li Shen, MBChB, PhDa,
- Lars Køber, MD, DMScb,
- William T. Abraham, MDd,
- Akshay S. Desai, MD, MPHe,
- Kenneth Dickstein, MD, PhDf,
- Milton Packer, MDg,
- Jean L. Rouleau, MDh,
- Scott D. Solomon, MDe,
- Karl Swedberg, MD, PhDi,
- Michael R. Zile, MDj,
- John J.V. McMurray, MDa,∗ (, )
- for the PARADIGM-HF and ATMOSPHERE Investigators
- aBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
- bDepartment of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
- cInserm CIC 1433, Université de Lorraine, CHRU de Nancy, Nancy, France
- dDivision of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio
- eCardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts
- fDepartment of Cardiology, University of Bergen, Stavanger University Hospital, Stavanger, Norway
- gBaylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas
- hInstitut de Cardiologie de Montréal, Université de Montréal, Montréal, Quebec, Canada
- iDepartment of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden, and National Heart and Lung Institute, Imperial College, London
- jDivision of Cardiology, Medical University of South Carolina, and Ralph H. Johnson Veterans Administration Medical Centre, Charleston, South Carolina
- ↵∗Address for correspondence:
Prof. John J. V. McMurray, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, United Kingdom.
Objectives This study examined the relationship between income inequality and heart failure outcomes.
Background The income inequality hypothesis postulates that population health is influenced by income distribution within a society, with greater inequality associated with worse outcomes.
Methods This study analyzed heart failure outcomes in 2 large trials conducted in 54 countries. Countries were divided by tertiles of Gini coefficients (where 0% represented absolute income equality and 100% represented absolute income inequality), and heart failure outcomes were adjusted for standard prognostic variables, country per capita income, education index, and hospital bed, and health worker density.
Results Of the 15,126 patients studied, 5,320 patients lived in Gini coefficient tertile 1 countries (coefficient: <33%), 6,124 patients lived in tertile 2 countries (33% to 41%), and 3,772 patients lived in tertile 3 countries (>41%). Patients in tertile 3 were younger than tertile 1 patients, were more often women, and had less comorbidity and several indicators of less severe heart failure, yet the tertile 3-to-1 hazard ratios (HR) for the primary composite outcome of cardiovascular death or heart failure hospitalization were 1.57 (95% confidence interval [CI]: 1.38 to 1.79) and 1.48 for all-cause death (95% CI: 1.29 to 1.71) after adjustment for recognized prognostic variables. After additional adjustments were made for per capita income, education index, hospital bed density, and health worker density, these HRs were 1.46 (95% CI: 1.25 to 1.70) and 1.30 (95% CI: 1.10 to 1.53), respectively.
Conclusions Greater income inequality was associated with worse heart failure outcomes, with an impact similar to those of major comorbidities. Better understanding of the societal and personal bases of these findings may suggest approaches to improve heart failure outcomes.
Heart failure (HF) is now recognized as a major public health problem not only in Western nations but also in low- and middle-income countries, reflecting the demographic changes and the epidemiological transition to noncommunicable diseases occurring in the latter countries (1). The growing recognition of the international importance of HF has been accompanied by studies highlighting the considerable differences in HF outcomes that exist among countries (2,3). Understanding the basis of these differences may help in tackling this increasing global problem. Some of the geographical variations in identified outcomes are attributable to differences in recognized prognostic factors such age, HF severity, and comorbidity. Other factors may also be pertinent, such as income inequality, which varies considerably internationally and is often particularly marked in low- and middle-income countries. The income inequality hypothesis postulates that population health is influenced by the degree to which income is unevenly distributed within a society (4,5). This hypothesis was developed to explain why large differences in population health are still observed in developed countries with high levels of income, as measured by gross domestic product (GDP) per capita (6,7). A variety of studies has shown a negative correlation between income inequality and life expectancy, infant mortality, and the incidence, prevalence, and burden of several diseases. The PARADIGM-HF (Prospective comparison of ARNI [Angiotensin Receptor Neprilysin Inhibitor] with ACEI [Angiotensin-Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and morbidity in Heart Failure) and the ATMOSPHERE (Aliskiren Trial to Minimize OutcomeS in Patients with Heart Failure) trials were 2 of the largest clinical trials in patients with HF with reduced ejection fraction (HFrEF) (8,9). The present study analyzed a pooled cohort of 15,216 participants from 54 of the 55 countries worldwide who were enrolled in the 2 trials to examine the potential association among different levels of income inequality and clinical characteristics and outcomes in patients with HFrEF.
Trials and participants
The design, baseline characteristics, and outcomes of the PARADIGM-HF and ATMOSPHERE trials have been published and are briefly described here (8,9). The inclusion and exclusion criteria of the 2 trials were almost identical. Patients were eligible at screening if they were ≥18 years of age and they had New York Heart Association (NYHA) functional class II to IV, a left ventricular ejection fraction (LVEF) ≤35% (changed from ≤40% initially PARADIGM-HF by amendment), elevated concentrations of natriuretic peptide (the cutoff level was independent of atrial fibrillation), and were taking an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) with a beta-blocker (unless contraindicated or not tolerated) and a mineralocorticoid receptor antagonist, if indicated. Exclusion criteria at screening included symptomatic hypotension or systolic blood pressure (SBP) <95 mm Hg (<90 mm Hg in ATMOSPHERE), an estimated glomerular filtration rate (eGFR) <30 ml/min per 1.73 m2 (<35 in ATMOSPHERE), and a potassium concentration of >5.4 mmol/l (>5.2 in ATMOSPHERE). The trial was approved by the ethics committees at all participating centers in 47 countries in PARADIGM-HF and in 43 countries in ATMOSPHERE. All patients provided written informed consent.
On trial entry, ongoing therapy with an ACE inhibitor or ARB was stopped, and patients entered a sequential run-in, first receiving enalapril, followed by sacubitril/valsartan in PARADIGM-HF and enalapril, followed by the combination of enalapril plus aliskiren in ATMOSPHERE. Patients who tolerated both of the run-in periods were randomly assigned to receive double-blinded therapy with sacubitril/valsartan or enalapril in a 1:1 ratio in PARADIGM-HF or enalapril or aliskiren or both drugs in a 1:1:1 ratio in ATMOSPHERE. PARADIGM-HF ran from December 2009 to May 2014, and ATMOSPHERE ran from May 2009 to October 2015 (median follow-up intervals were 27 months and 36.6 months, respectively) (8,9).
The impact of income inequality was evaluated using the Gini coefficient, which is derived from the Lorenz curve (Online Figure S1), in which 0 (0%) indicates absolute income equality and 1 (100%) indicates absolute income inequality. For most countries, Gini coefficients were obtained from the United Nations Development Programme (UNDP) (10). Data from 2003 were used to account for a lag effect, whereby a state of inequality dating back 15 years might have had a stronger association with health than current income inequality (11). For countries where a Gini coefficient for 2003 was unavailable, a value from the year closest to 2003 was used. Gini coefficients for Hong Kong, Japan, Korea, and Singapore were derived from other sources. Taiwan was excluded from the analysis because social indicators could not be derived from UNDP and because reports from other sources were inconsistent and unreliable.
Patients were divided into 3 groups by tertiles according to the distribution of Gini coefficients. Group 1 countries (least inequality) had a Gini coefficient of <33, group 2 consisted of those countries with Gini coefficients between 33 and 41 and group 3 countries (greatest inequality) had Gini coefficients of >41. The association between income inequality and outcomes was also tested using the Gini coefficient as a continuous variable.
Other socioeconomic indicators
To adjust for other socioeconomic variables, additional information was also collected, including national per capita income (in US$ from the World Bank) (12), hospital bed density (from The World Factbook) (13), and health worker density (from the World Health Organization) (14) per 1,000 population. The education index was derived from the Human Development Index from the UNDP database (15), for further analysis of outcomes, as discussed subsequently. To derive health worker density, the average densities of physicians and nurses/midwives were used as figures for other types of health care workers that were not uniformly available from all countries. All figures were ascertained for 2013 or the closest year to 2013.
The primary outcome for both trials was the composite value of the first hospitalization for HF or cardiovascular death. In the present study, the associations between income inequality, as reflected in the Gini coefficient, the risk of the primary outcome and each of its components, and all-cause mortality were investigated. All endpoints were adjudicated by the same clinical endpoint committee according to pre-specified criteria.
Baseline characteristic values are proportions, mean ± SD, and median (interquartile range [IQR]). Statistical methods used to analyze baseline characteristics were analysis of variance, the chi-square test, and the Kruskal-Wallis rank test for nonparametric values. Competing risk regression was carried out using the Fine-Gray model to analyze the outcomes of interest, using 3 models (16). All-cause mortality was analyzed using Cox regression. Model 1 was used to calculate the crude hazard ratio (HR) for each outcome. Model 2 fitted age, sex, heart rate, SBP, body mass index, NYHA functional class, LVEF, eGFR, and N-terminal pro–B-type natriuretic peptide (NT-proBNP). Model 3 fitted per capita income, education index, hospital bed density, and health worker density, in addition to the variables used in Model 2. Results from a multilevel Cox regression model were compared with those from another Cox model, which adjusted only for region, and found very little variability to account for random effects (17). Consequently, all models were adjusted for region along with randomized treatment at baseline. Schoenfeld residuals were used to test the proportional hazards assumption. Values of p < 0.05 were considered significant. All analyses were conducted using Stata version 14 software (StataCorp, College Station, Texas).
Overall, 15,126 patients from 54 countries were included (Table 1 and Online Table S1). The median Gini coefficient was 35.1 (range: 25.9 to 64.8; 25th and 75th percentile: 31.9 and 40.9, respectively). The mean was 38.1 (9). The highest Gini coefficient tertile (tertile: 3; coefficient: >41; greatest inequality) included 3,772 patients in 17 countries from 4 of the 5 global regions (North America was excluded) (Figure 1). The middle tertile (33 to 41) included 6,124 individuals in 19 countries from all 5 regions, and the lowest tertile (tertile: 1; coefficient: <33; least inequality) included 5,320 patients in 18 countries from 3 of the 5 regions (North America and Latin America were excluded) (Figure 1).
As the Gini coefficient increased, the human development index, the per capita income, the proportion of GDP spent on health care, and the hospital bed density decreased (Table 1).
Patient characteristics varied considerably by income inequality (Table 1). A higher proportion of patients in Gini tertile 3 countries were women (24.8% vs. 21.0%, respectively, in tertile 1, and 20.8%, respectively, in tertile 2). Patients in Gini tertile 3 countries were younger (61 vs. 66 and 63 years of age, respectively), and fewer were obese (23.7% vs. 34.8% and 30.5%, respectively). Gini tertile 3 countries had the highest proportion of people who never smoked and lower consumption of alcohol, whereas tertile 1 countries had the highest proportions of smokers and heavier consumers of alcohol.
Gini tertile 3 countries had the lowest prevalence of all recorded comorbid conditions, including hypertension, diabetes, atrial fibrillation, stroke, chronic obstructive pulmonary disease, and renal disease (Table 1). By contrast, Gini tertile 1 countries had the highest prevalence of all comorbid conditions, with the single exception of unstable angina (but not myocardial infarction [MI]), which was slightly more common in tertile 2 than in tertile 1 countries.
Heart failure characteristics
In keeping with the pattern of comorbidity, Gini tertile 3 patients were the least likely to have HF caused by ischemia (Table 1). Gini tertile 3 patients had the highest proportion of patients with a more recent diagnosis of HF, although all groups had a similar proportion of patients with a prior HF hospitalization. Gini tertile 3 patients had the highest proportion of patients in NYHA functional classes I/II and the highest (best) Kansas City Cardiomyopathy Questionnaire scores. LVEF differed little across Gini tertiles. However, the median NT-proBNP concentration was highest in Gini tertile 3 patients (1,500 pg/ml; IQR: 803 to 3,130 pg/ml), and the lowest level was seen in tertile 1 patients (1,358 pg/ml; IQR: 766 to 2,540 pg/ml).
Gini tertile 3 patients had the lowest prevalence of dyspnea on effort, paroxysmal nocturnal dyspnea, third heart sound, and peripheral edema. Patients in tertile 3 also had the lowest SBP (120 vs. 125 mm Hg, respectively, in tertile 1, and 122 mm Hg in tertile 2). Gini tertile 3 patients had the highest average eGFR level, and tertile 1 patients had the lowest eGFR (Table 1).
Baseline drugs, devices, and other therapies
Gini tertile 3 patients were least often treated with a diuretic and most often treated with a mineralocorticoid receptor antagonist and digoxin (despite the lower prevalence of atrial fibrillation). Pre-trial use of an ARB (instead of an ACE inhibitor) was most common in tertile 3 countries (Table 1). Use of devices was lowest in tertile 3 patients, in whom the use of cardiac resynchronization therapy with a pacemaker (CRT-P) or a defibrillator (CRT- D) was 2.7%, and the use of an implantable cardioverter-defibrillator or CRT-D was 4.4%, respectively; whereas the use of these devices was intermediate in tertile 2 patients (6.8% and 16.1%, respectively) and highest in individuals in tertile 1 countries (8.3% and 21.3%, respectively). Prior coronary revascularization (and statin therapy) showed similar patterns (Table 1).
Composite outcome and mortality
Patients in Gini tertile 3 had the highest rate of primary composite outcome (13.7 per 100 person-years), and the rate was intermediate in tertile 2 (11.7 per 100 person-years) and lowest in tertile 1 (10.9 per 100 person-years) (Table 2, Figure 2). This trend was also observed for both of the rates of cardiovascular and all-cause death, which were highest in tertile 3 patients (8.9 and 10.4, respectively) and lowest in tertile 1 patients (5.9 and 7.4, respectively) (Table 2, Figure 2).
In the model that was adjusted for conventional prognostic variables, including NT-proBNP, patients in Gini tertile 3 remained at significantly higher risk of the primary composite outcome (57% higher risk) and of cardiovascular and all-cause death (55% and 48% higher, respectively) (Table 2).
When country per capita income, education index, hospital bed density, and health worker density were added to the multivariate models, the elevated risk in Gini tertile 3 patients was attenuated but remained significant (46%, 35%, and 30% higher for the primary composite outcome, cardiovascular death, and all-cause mortality, respectively) (Table 2). When the Gini coefficient was considered a continuous rather than a categorical variable, it remained an independent predictor of outcomes. Each 10-point increase in Gini coefficient was associated with a higher risk of cardiovascular death (HR: 1.16; 95% confidence interval [CI]: 1.04 to 1.29; p = 0.005) and death from any cause (HR: 1.15; 95% CI: 1.04 to 1.26; p = 0.006) (Online Table S2, Figure 3). As seen in Figure 3, the impact of a 10-point increase in Gini coefficient on cardiovascular death was greater than that of most other predictive variables, including advancing age and previous MI.
Hospital admission for heart failure
The unadjusted rate of HF hospitalization was highest in Gini tertile 3 patients but intermediate in tertile 1 rather than tertile 2 patients, as it was for the other outcomes. In adjusted model 2, risk of hospital admission for HF was 92% higher in Gini tertile 3 than in tertile 1 patients (HR: 1.92; 95% CI: 1.58 to 2.33) (Table 2).
In this study of 15,126 HFrEF patients from 54 countries, a statistically significant and clinically substantial association was found between income inequality, patient characteristics, and disease outcomes. These differences persisted after adjustments were made for recognized, patient-level prognostic variables, as well as for country per capita income.
Over the past 20 years, a substantial body of evidence has accrued in support of an association between income inequality and a variety of measurements of population health. The income inequality hypothesis states that an individual’s health is affected not only by his or her own income but also by the distribution of income in that person’s society, especially in high-income countries. Consistent with this hypothesis, countries sharing the same GDP may have quite different health outcomes, reflecting the distribution of income within those societies. That is, it appears that it is not only the wealth of a society but the distribution of wealth within that society that influences health. Although these relationships are well established for broad health outcomes such as childhood and overall mortality, there are few studies of specific diseases, especially cardiovascular disease (CVD). However, in one analysis involving 78 countries, income inequality was independently and positively associated with disability-adjusted life years and mortality related to coronary heart disease (CHD) and coronary risk factors (18). In another investigation, confined to the United States, a state-level analysis of the National Longitudinal Mortality Study showed that a 0.1-unit higher Gini coefficient predicted a 1% higher probability of dying from CHD (19). The present study extended this examination of the relationship between income disparity and cardiovascular health to HF.
The baseline characteristics, medical history, and background treatment of patients differed markedly according to income inequality but perhaps not predictably or intuitively, given the association between higher Gini coefficient and worse outcomes. For example, patients in countries with the highest Gini coefficient (tertile 3; greatest income inequality) were, on average, 5 years younger than those in the lowest tertile countries, and they were more often women who had less comorbidity, had an ischemic cause less often, had HF more recently diagnosed, had a better NYHA functional class profile and Kansas City Cardiomyopathy Questionnaire score, and had the highest mean eGFR. These are all features that were expected to track with better rather than worse outcomes, which could be attributable to the fact that patients in Gini tertile 3 were younger (20). Indeed, only a few variables associated with a poor prognosis were more unfavorable in the Gini coefficient tertile 3 patients, including an average LVEF that was lower (−1.9%) in tertile 3 patients than in tertile 1 patients, as was SBP (−5.2 mm Hg), whereas median NT-proBNP levels were somewhat higher (+142 pg/ml). There were also some treatment differences among the groups that were more expected, for example, digoxin (which is inexpensive) was used most often in tertile 3 patients, whereas devices (which are more expensive) were used much less often.
Even after correcting for patient-level biological characteristics known to predict outcomes, including the most powerful of these, NT-proBNP, patients in Gini tertile 3 had considerably higher mortality than those in tertile 1. Indeed, the adjusted HR was 1.48 (95% CI: 1.29 to 1.71) for all-cause death and 1.55 (95% CI: 1.32 to 1.82) for death from cardiovascular causes. Because population health and life-expectancy are also associated with overall country affluence, per capita income, which attenuated but did not eliminate the relationship between income disparity and mortality (with a remaining excess risk ranging from 20% to 30%), was also adjusted for. This disconnect between mortality and clinical presentation in Gini tertile 3 is difficult to explain but is most likely a function of the unfavorable effects of income inequality.
Additional adjustments for education index, hospital bed density, and physician density also did not attenuate the greater risk of the composite outcome among patients in Gini tertile 3, with a fully adjusted HR of 1.46 (95% CI: 1.25 to 1.70). When the risk of HF hospitalization alone was examined (but accounting for the competing risk of death), it was also found to be highest in countries with the greatest income disparity. Those countries also had the lowest bed density, suggesting that admission rates are not just a function of bed availability.
The large size of the “effect” of income inequality on HF outcomes is worthy of comment. The adjusted risks of the fatal outcomes were approximately 20% to 30% higher in individuals living in the tertile of countries with the widest income distribution. This magnitude of differences was similar to or greater than that attributable to other major comorbidities such as diabetes or previous MI. The risk associated with a 10-unit increase in Gini coefficient was also analyzed, noting that the differences between the median coefficient in tertiles 1 and 3 was 20 units. The excess risk for cardiovascular mortality per 10-unit increase in Gini coefficient was 16%, similar to the risk associated with a 10% decrease in LVEF, a decrease of 27 mm Hg in SBP, or a decrease of 27 ml/min per 1.73 m2 in eGFR.
Countries were divided according to thirds of Gini coefficient, giving tertiles of <33%, 33% to 41%, and >41%. There is generally no consensus for the categorization of nations according to Gini coefficient, although in a study by Kim and colleagues (18), which examined CHD and stroke, countries were divided into “low” (<0.38), “medium” (95% CI: 0.38 to 0.55), and “high” (>0.55) Gini coefficient groups (using a scale of 0 to 1.0). In a meta-analysis of 9 multilevel longitudinal studies including nearly 60 million participants, Kondo et al. (21) reported a relative risk of 1.08 (95% CI: 1.06 to 1.10) for all-cause mortality per 0.05-unit increase in Gini coefficient (using a scale of 0 to 1.0). Analysis of the present study showed an equivalent increase in Gini coefficient (5 points on a scale of 0 to 100) was associated with an HR of 1.07 (95% CI: 1.02 to 1.12; p = 0.006); that is, an excess risk of similar magnitude.
Of course, the key question about the present findings, and those about income inequality health hypothesis generally, is why should greater income disparity be associated with worse health outcomes? Many theories have been expounded. One way to consider these outcomes is under the broad headings of “societal-structural” and “psychosocial” explanations.
The “societal-structural” explanations are numerous and complex, and not all are necessarily relevant to outcomes in patients with an established clinical condition (as opposed to the future development of disease) (22,23). Many of these explanations focus on the corrosive effects of income inequality on society, leading to loss of social cohesion and divergence between the interests of the rich and those of the poor. It is argued that income inequality leads to the decreased willingness of societies to invest in social services and welfare programs, broad access to health care services, and safety nets (24,25). These effects may lead to distortions of health care priorities and spending and can be exacerbated by geographical concentrations of hospitals and physicians in more affluent areas, with provision of medically unnecessary services and performance of discretionary procedures in these areas. Conversely, there may be underinvestment in health care infrastructure and resources in areas of greater need, with reduced access to and affordability of health care for the neediest (25). Potentially, each of these factors could lead to a higher prevalence of disease, delayed care, more advanced disease at presentation, more preventable hospital admissions, and ultimately, more premature deaths. It is also easy to see how a syndrome as complicated as HF, with its need for integration of primary and secondary health care services, multidisciplinary management programs, appropriate exercise prescription, complex polypharmacy and attendant electrolyte monitoring, tailored treatment of physical and psychological comorbidity, appropriate selection of devices, and ultimately, provision of palliative care may be particularly affected by gaps in services and aggravated by failure of social and family networks related to loss of social cohesion (26).
Some of these societal issues may also be greater in low- and middle-income countries undergoing epidemiologic transitions from infectious diseases to noncommunicable diseases (27). Here, health strategies and policies need to change, but these countries often display a high level of income disparity, despite (or because of) accelerated economic growth in many cases (28).
Among the psychosocial explanations, the one that is of most interest in HF is the belief that chronic stress as a consequence of the income inequality described above has detrimental psychoneuroendocrine effects (18). There is long-standing evidence that stress may be involved in at least some types of CVDs. For example, in the INTERHEART study, Rosengren et al. (29) found that psychosocial stressors were associated with a higher risk of acute MI. Chronic stress is associated with memory impairment, anxiety, and depression, all of which are common in HF and potentially harmful because of adverse effects on adherence and self-management (30,31). Moreover, recent evidence has suggested even more widespread biological consequences of stress including reduced immune responses and impaired endothelial function (32).
Study strengths and limitations
To the best of the present authors' knowledge, the current study is the first to investigate the association between income inequality and outcomes in HF (or any chronic disease) transnationally. However, the present study is based on a highly selected clinical trial population recruited from specific centers and may not necessarily represent the general population.
Not all the countries in this analysis were from similar income categories, and information on individual socioeconomic status was missing, but adjustment was made for per capita income representing population-level income for each country. Accordingly, differences in health care systems were not adjusted because most of the countries did not follow any particular health care system (33). An attempt was made to make up for those shortcomings to a certain degree by including information about hospital bed density and health worker density per 1,000 population. Patients were mandated by protocol to have been receiving ACE inhibitor (or ARB) therapy and beta-blocker therapy at the time of screening. There was also poor representation from Africa in the analysis (only patients from South Africa were included). A measurement that might have supported or refuted a “psychosocial” explanation for the association between greater income disparity and poor outcomes was lacking.
COMPETENCY IN MEDICAL KNOWLEDGE: HF poses an enormous economic burden on society. It is the leading cause of hospitalization in Western countries and is steadily increasing in prevalence (and is especially concerning in younger people) in developing countries. In countries with prominent levels of income inequality, unfavorable social actors coupled with inadequate and inefficient public spending on health care may present considerable barriers not only to the prevention of CVD (the focus of most studies to date) but also to the improvement of outcomes in patients with established and chronic diseases such as HF.
TRANSLATIONAL OUTLOOK: If indeed income inequality does influence HF outcomes, both developing and developed nations need to consider how their public health policies can be modified to more effectively tackle this growing global epidemic.
The ATMOSPHERE and PARADIGM-HF trials were funded by Novartis directly to authors or to their institutions for participation in one or both of these trials (except for Drs. Dewan, Rørth, Shen, Ferreira, and Zannad).
- Abbreviations and Acronyms
- estimated glomerular filtration rate
- heart failure with reduced ejection fraction
- Kansas City Cardiomyopathy Questionnaire
- left ventricular ejection fraction
- N-terminal pro–B-type natriuretic peptide
- New York Heart Association
- Received August 22, 2018.
- Revision received October 29, 2018.
- Accepted November 2, 2018.
- 2018 The Authors
- Callender T.,
- Woodward M.,
- Roth G.,
- et al.
- Dokainish H.,
- Teo K.,
- Zhu J.,
- et al.
- Kaplan G.A.,
- Pamuk E.R.,
- Lynch J.W.,
- Cohen R.D.,
- Balfour J.L.
- Wilkinson R.G.
- ↵United Nations. United Nations Development Programme. Income Gini Coefficient. Human Development Reports. 2013. Available at: http://hdr.undp.org/en/content/income-gini-coefficient. Accessed November 16, 2018.
- Blakely T.A.,
- Kennedy B.P.,
- Glass R.,
- Kawachi I.
- ↵The World Bank. GDP per Capita (Current US$). 2017. Available at: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed November 16, 2018.
- ↵Central Intelligence Agency. FIELD LISTING: RELIGIONS. The World Fact Book. Washington, DC; 2017:1–119. Available at: https://www.cia.gov/library/publications/the-world-factbook/. Accessed November 16, 2018.
- ↵World Health Organization. Global Health Observatory Data Repository. Density per 1,000; Data by Country. Geneva, Switzerland; WHO. Available at: http://apps.who.int/gho/data/node.main.A1444. Accessed November 16, 2018.
- ↵United Nations. United Nations Development Programme. Human Development Data (1980-2015). | Human Development Reports. 2016. Available at: http://hdr.undp.org/en/data. Accessed November 16, 2018.
- Austin P.C.
- Kim D.
- Green C.P.,
- Porter C.B.,
- Bresnahan D.R.,
- Spertus J.A.
- Kondo N.,
- Sembajwe G.,
- Kawachi I.,
- Van Dam R.M.,
- Subramanian S.V.,
- Yamagata Z.
- López D.B.,
- Loehrer A.P.,
- Chang D.C.
- Carrieri V.,
- Wuebker A.
- Lindenauer P.K.,
- Lagu T.,
- Rothberg M.B.,
- et al.
- Reddy K.S.,
- Yusuf S.
- Rosengren A.,
- Hawken S.,
- Ounpuu S.,
- et al.
- Rutledge T.,
- Reis V.A.,
- Linke S.E.,
- Greenberg B.H.,
- Mills P.J.
- ↵Physicians for a National Health Program. Health Care Systems-Four Basic Models. Chicago, IL: PNHP. Available at: http://www.pnhp.org/single_payer_resources/health_care_systems_four_basic_models.php. Accessed November 16, 2018.